Autolus Therapeutics Highlights obe-cel Momentum in ALL With New Real-World ROKA and Pediatric Data [Yahoo! Finance]
Autolus Therapeutics plc - American Depositary Shares (AUTL)
Last autolus therapeutics plc - american depositary shares earnings: 11/7 07:06 am
Check Earnings Report
US:NASDAQ Investor Relations:
autolus.com/investor-relations
Company Research
Source: Yahoo! Finance
70% MRD-negative complete remissions, while safety appeared favorable (˜50% any-grade CRS with no higher-grade CRS reported and ~17% mostly grade-1 ICANS) in the presented cohort. The FELIX trial reported a 77% overall response rate with a subset achieving durable remissions (including 3 years without transplant), and investigators are testing obe-cel as a frontline consolidation to deepen responses and potentially spare some patients from allogeneic transplant. In pediatrics, the CATALYST phase Ib showed strong results—of evaluable patients 21/22 responded and 20 achieved complete remission with all responders MRD-negative—alongside low rates of severe CRS, consistent manufacturing, and plans to expand to ~54 pediatric patients for regulatory support. Interested in Autolus Therapeutics PLC Sponsored ADR? Here are five stocks we like better. Autolus Therapeutics (NASDAQ:AUTL) hosted an investor event focused on its acute lymphoblastic leukemia (ALL) program, featuring clinicia
Show less
Read more
Impact Snapshot
Event Time:
AUTL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AUTL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AUTL alerts
High impacting Autolus Therapeutics plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AUTL
News
- Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative ‘personalized off-the-shelf’ immunotherapy toward clinical developmentGlobeNewswire
- Autolus Therapeutics (AUTL) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $10.00 price target on the stock.MarketBeat
- Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights Transcript [Seeking Alpha]Seeking Alpha
- Autolus Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswire
- Mizuho Lowers its Price Target on Autolus Therapeutics plc (AUTL) to $10 from $12 [Yahoo! Finance]Yahoo! Finance
AUTL
Earnings
- 3/27/26 - Miss
AUTL
Sec Filings
- 4/16/26 - Form 8-K
- 4/15/26 - Form DEL
- 4/15/26 - Form DEL
- AUTL's page on the SEC website